Effects of prostaglandin analogues on aqueous humor outflow pathways

Nelson S. Winkler, Michael P Fautsch

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Elevated intraocular pressure (IOP) is the most prevalent risk factor for glaucoma. All treatments, whether surgical or pharmaceutical, are aimed at lowering IOP. Prostaglandin analogues are a first line therapy for glaucoma due to their ability to reduce IOP, once-daily dosing, efficacy, and minimal side-effect profile. Whereas prostaglandin analogues have been known to alter aqueous humor outflow through the unconventional (uveoscleral) pathway, more recent evidence suggests their action also occurs through the conventional (trabecular) pathway. Understanding how prostaglandin analogues successfully lower IOP is important, as this information may lead to the discovery of new molecular targets for future therapeutic intervention. This review explores the current understanding of prostaglandin analogue biology as it pertains to IOP reduction and improved aqueous humor outflow facility.

Original languageEnglish (US)
Pages (from-to)102-109
Number of pages8
JournalJournal of Ocular Pharmacology and Therapeutics
Volume30
Issue number2-3
DOIs
StatePublished - Mar 1 2014

Fingerprint

Synthetic Prostaglandins
Aqueous Humor
Intraocular Pressure
Glaucoma
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Ophthalmology
  • Pharmacology
  • Medicine(all)

Cite this

Effects of prostaglandin analogues on aqueous humor outflow pathways. / Winkler, Nelson S.; Fautsch, Michael P.

In: Journal of Ocular Pharmacology and Therapeutics, Vol. 30, No. 2-3, 01.03.2014, p. 102-109.

Research output: Contribution to journalArticle

@article{5a186e3bd5d747c2b7e3d88640b57784,
title = "Effects of prostaglandin analogues on aqueous humor outflow pathways",
abstract = "Elevated intraocular pressure (IOP) is the most prevalent risk factor for glaucoma. All treatments, whether surgical or pharmaceutical, are aimed at lowering IOP. Prostaglandin analogues are a first line therapy for glaucoma due to their ability to reduce IOP, once-daily dosing, efficacy, and minimal side-effect profile. Whereas prostaglandin analogues have been known to alter aqueous humor outflow through the unconventional (uveoscleral) pathway, more recent evidence suggests their action also occurs through the conventional (trabecular) pathway. Understanding how prostaglandin analogues successfully lower IOP is important, as this information may lead to the discovery of new molecular targets for future therapeutic intervention. This review explores the current understanding of prostaglandin analogue biology as it pertains to IOP reduction and improved aqueous humor outflow facility.",
author = "Winkler, {Nelson S.} and Fautsch, {Michael P}",
year = "2014",
month = "3",
day = "1",
doi = "10.1089/jop.2013.0179",
language = "English (US)",
volume = "30",
pages = "102--109",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "2-3",

}

TY - JOUR

T1 - Effects of prostaglandin analogues on aqueous humor outflow pathways

AU - Winkler, Nelson S.

AU - Fautsch, Michael P

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Elevated intraocular pressure (IOP) is the most prevalent risk factor for glaucoma. All treatments, whether surgical or pharmaceutical, are aimed at lowering IOP. Prostaglandin analogues are a first line therapy for glaucoma due to their ability to reduce IOP, once-daily dosing, efficacy, and minimal side-effect profile. Whereas prostaglandin analogues have been known to alter aqueous humor outflow through the unconventional (uveoscleral) pathway, more recent evidence suggests their action also occurs through the conventional (trabecular) pathway. Understanding how prostaglandin analogues successfully lower IOP is important, as this information may lead to the discovery of new molecular targets for future therapeutic intervention. This review explores the current understanding of prostaglandin analogue biology as it pertains to IOP reduction and improved aqueous humor outflow facility.

AB - Elevated intraocular pressure (IOP) is the most prevalent risk factor for glaucoma. All treatments, whether surgical or pharmaceutical, are aimed at lowering IOP. Prostaglandin analogues are a first line therapy for glaucoma due to their ability to reduce IOP, once-daily dosing, efficacy, and minimal side-effect profile. Whereas prostaglandin analogues have been known to alter aqueous humor outflow through the unconventional (uveoscleral) pathway, more recent evidence suggests their action also occurs through the conventional (trabecular) pathway. Understanding how prostaglandin analogues successfully lower IOP is important, as this information may lead to the discovery of new molecular targets for future therapeutic intervention. This review explores the current understanding of prostaglandin analogue biology as it pertains to IOP reduction and improved aqueous humor outflow facility.

UR - http://www.scopus.com/inward/record.url?scp=84898756412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898756412&partnerID=8YFLogxK

U2 - 10.1089/jop.2013.0179

DO - 10.1089/jop.2013.0179

M3 - Article

C2 - 24359106

AN - SCOPUS:84898756412

VL - 30

SP - 102

EP - 109

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 2-3

ER -